A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) As A Single Agent And In Combination With Defactinib (FAK Inhibitor) In Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)